# Supplementary Materials: Early AbobotulinumtoxinA (Dysport®) in Post-Stroke Adult Upper Limb Spasticity: ONTIME Pilot Study

**Raymond L Rosales, Jovita Balcaitiene, Hugues Berard, Pascal Maisonobe, Khean Jin Goh, Witsanu Kumthornthip, Mazlina Mazlan, Lydia Abdul Latif, Mary Mildred D. Delos Santos, Chayaporn Chotiyarnwong, Phakamas Tanvijit, Odessa Nuez and Keng He Kong**

**Table S1.** Baseline characteristics for patients in the ONTIME study (ITT population).

| | **AbobotulinumtoxinA 500 U (*N* = 28)** | **Placebo (*N* = 14)** | **All patients (*N* = 42)** |
|---|---|---|---|
| Age in years, mean (SD) [range] | 61.5 (13.2) [32, 80] | 56.5 (9.7) [33, 72] | 59.8 (12.3) [32, 80] |
| Sex, *n* (%) | | | |
| Male | 23 (82.1) | 10 (71.4) | 33 (78.6) |
| Female | 5 (17.9) | 4 (28.6) | 9 (21.4) |
| Country, *n* (%) | | | |
| Malaysia | 3 (10.7) | 1 (7.1) | 4 (9.5) |
| Philippines | 11 (39.3) | 4 (28.6) | 15 (35.7) |
| Singapore | 9 (32.1) | 5 (35.7) | 14 (33.3) |
| Thailand | 5 (17.9) | 4 (28.6) | 9 (21.4) |
| Time in weeks since stroke diagnosis, mean (SD) [range] | 6.18 (2.87) [2.3, 11.7] | 6.52 (2.53) [2.9, 11.3] | 6.29 (2.73) [2.3, 11.7] |
| Type of stroke, *n* (%) | | | |
| Ischemic | 20 (71.4) | 10 (71.4) | 30 (71.4) |
| Hemorrhagic | 8 (28.6) | 4 (28.6) | 12 (28.6) |
| Arm affected, *n* (%) | | | |
| Left | 16 (57.1) | 8 (57.1) | 24 (57.1) |
| Right | 12 (42.9) | 6 (42.9) | 18 (42.9) |
| Both | 0 | 0 | 0 |
| mRS score at baseline, mean (SD) [range] | 3.9 (0.5) [3, 5] | 3.8 (0.4) [3, 4] | 3.9 (0.5) [3, 5] |
| Disposition of patients by mRS score at baseline, *n* (%) | | | |
| 0-No symptoms | 0 | 0 | 0 |
| 1-No significant disability | 0 | 0 | 0 |
| 2-Slight disability | 0 | 0 | 0 |
| 3-Moderate disability | 5 (17.9) | 3 (21.4) | 8 (19.0) |
| 4-Moderately severe disability | 20 (71.4) | 11 (78.6) | 31 (73.8) |
| 5-Severe disability | 3 (10.7) | 0 | 3 (7.1) |
| Primary targeted muscles, *n* (%) | | | |
| Elbow flexors | 20 (71.4) | 11 (78.6) | 31 (73.8) |
| Elbow pronators | 4 (14.3) | 0 | 4 (9.5) |
| Wrist flexors | 4 (14.3) | 2 (14.3) | 6 (14.3) |
| Finger flexors | 0 | 1 (7.1) | 1 (2.4) |
| Spasticity at baseline, *n* (%) | | | |
| Symptomatic | 22 (78.6) | 10 (71.4) | 32 (76.2) |
| Asymptomatic | 6 (21.4) | 4 (28.6) | 10 (23.8) |

| | | | |
|---|---|---|---|
| MAS, mean (SD) [range] | 2.11 (0.31) [2.0, 3.0] | 2.14 (0.36) [2.0, 3.0] | 2.12 (0.33) [2.0, 3.0] |
| Passive function (Likert scale), *n* (%) | | | |
| 0-No impact | 8 (28.6) | 7 (50.0) | 15 (35.7) |
| 1-Mild impact | 6 (21.4) | 4 (28.6) | 10 (23.8) |
| 2-Moderate impact | 11 (39.3) | 1 (7.1) | 12 (28.6) |
| 3-Severe impact | 3 (10.7) | 2 (14.3) | 5 (11.9) |
| Active function (Likert scale), *n* (%) | | | |
| 0-No impact | 11 (39.3) | 7 (50.0) | 18 (42.9) |
| 1-Mild impact | 3 (10.7) | 1 (7.1) | 4 (9.5) |
| 2-Moderate impact | 10 (35.7) | 3 (21.4) | 13 (31.0) |
| 3-Severe impact | 4 (14.3) | 3 (21.4) | 7 (16.7) |
| Involuntary movements (Likert scale), *n* (%) | | | |
| 0-No involuntary movements | 15 (53.6) | 7 (50.0) | 22 (52.4) |
| 1-Mild impact | 6 (21.4) | 3 (21.4) | 9 (21.4) |
| 2-Moderate impact | 6 (21.4) | 3 (21.4) | 9 (21.4) |
| 3-Severe impact | 1 (3.6) | 1 (7.1) | 2 (4.8) |
| Numeric Pain Rating Scale | | | |
| Score of > 4, *n* (%) | 12 (42.9) | 4 (28.6) | 16 (38.1) |
| Mean score (SD) [range] | 3.1 (3.2) [0, 10.0] | 3.1 (2.7) [0, 10.0] | 3.1 (3.0) [0, 10.0] |

ITT, intention-to-treat; MAS, Modified Ashworth Scale; mRS, modified Rankin Scale; SD, standard deviation.

**Table S2.** Concomitant non-drug therapy use (safety population).

| | **AbobotulinumtoxinA 500 U (*N* = 28)** | **Placebo (*N* = 14)** | **All patients (*N* = 42)** |
|---|---|---|---|
| Any concomitant non-drug therapies, *n* (%) | 25 (89.3) | 14 (100.0) | 39 (92.9) |
| Occupational therapy | 8 (28.6) | 5 (35.7) | 13 (31.0) |
| Physiotherapy | 22 (78.6) | 14 (100.0) | 36 (85.7) |
| Duration in days of physiotherapy, mean (SD) [range] | 157.9 (59.2) [70, 230] | 126.1 (55.0) [59, 271] | - |

SD, standard deviation.

**Table S3.** Concomitant post-stroke medications by therapeutic class (safety population).

| **Therapeutic class, *n* (%)** | **AbobotulinumtoxinA 500 U (*N* = 28)** | **Placebo (*N* = 14)** | **All patients (*N* = 42)** |
|---|---|---|---|
| Any concomitant medication | 3 (10.7) | 3 (21.4) | 6 (14.3) |
| Muscle relaxants | 1 (3.6) | 2 (14.3) | 3 (7.1) |
| Antiepileptics | 1 (3.6) | 1 (7.1) | 2 (4.8) |
| Analgesics | 1 (3.6) | 0 | 1 (2.4) |
| Lipid-modifying agents | 1 (3.6) | 0 | 1 (2.4) |

Prior and concomitant medications were recorded at the each study visit.